DB01283ApprovedWithdrawnSmall molecule
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in... New Zealand and Canada have also followed suit in recalling the drug.
- Mechanism
- Curator reviewed
The mechanism of action of lumiracoxib is due to inhibition of prostaglandin synthesis via inhibition of cyclooygenase-2 (COX-2). Lumiracoxib does not inhibit COX-1 at therapeutic concentrations.
- Primary indication
- For the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.Curator reviewed
- Formula / weight
- C15H13ClFNO2 · 293.721 g/mol (avg)
- Code names
- COX-189
Resolves to
Clinical / RWD
Structure
InChIKey
KHPKQFYUPIUARC-UHFFFAOYSA-NSMILESCC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1Targets
What you can answer from here — as of September 23, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Lumiracoxib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account